Long-Term Liabilities: The sum of all non-current liabilities.
Revelation Biosciences, Inc. (REVB) had Long-Term Liabilities of $0.55M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-3.32M |
|
-- |
|
-- |
|
$3.66M |
|
$-3.66M |
|
$0.34M |
|
$-3.32M |
|
$-3.32M |
|
$-3.32M |
|
$-3.32M |
|
$-3.32M |
|
$-3.32M |
|
$-3.66M |
|
$-3.65M |
|
3.83M |
|
3.83M |
|
$-0.87 |
|
$-0.87 |
|
| Balance Sheet Financials | |
$11.68M |
|
$0.17M |
|
$0.81M |
|
$12.50M |
|
$1.88M |
|
-- |
|
|
Long-Term Liabilities |
$0.55M |
$2.43M |
|
$10.07M |
|
$10.07M |
|
$10.07M |
|
3.91M |
|
| Cash Flow Statement Financials | |
$-5.77M |
|
$-0.11M |
|
$6.67M |
|
$10.70M |
|
$11.48M |
|
$0.78M |
|
$0.87M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.21 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-5.88M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-33.01% |
|
-33.01% |
|
-26.59% |
|
-33.01% |
|
$2.58 |
|
$-1.54 |
|
$-1.51 |
|